Financial Data and Key Metrics Changes - For Q4 2022, GAAP revenues were $298 million, exceeding the top end of the revised guidance range by $3 million [11] - Q4 2022 GAAP earnings per share (EPS) were a loss of $0.64, compared to income of $0.37 in the previous quarter and income of $0.28 in Q4 2021 [12] - Full year 2022 GAAP revenues reached $1.296 billion, a 14% increase from the previous year [36][122] - Full year 2022 non-GAAP EPS was $3, a decrease of 21% from 2021 [19] - Full year 2022 free cash flow was $17 million, a decrease of $156 million from the previous year [21] Business Line Data and Key Metrics Changes - Bookings for full year 2022 were $1.054 billion, a 13% decrease from $1.217 billion in 2021, primarily due to a slowdown in point-of-care bookings [15] - Advanced Services backlog as of December 31, 2022, was $418 million, with $50 million in short-term backlog and $369 million in long-term backlog [120] - Non-GAAP gross margin for Q4 2022 was 45.3%, a decrease of 220 basis points from the previous quarter [13] Market Data and Key Metrics Changes - The company noted that many health systems implemented capital budget freezes, elongating sales cycles, particularly impacting the point-of-care business [8] - Despite the macroeconomic challenges, the company observed stabilization in the healthcare environment in Q4 2022 and early 2023 [9][41] Company Strategy and Development Direction - The company plans to continue R&D investment across its Advanced Services portfolio in 2023, focusing on integrating technology platforms from recent acquisitions [6] - The strategic focus includes transitioning to a next-generation cloud-native capability to transform the pharmacy care delivery model [32] - The company aims to reduce operating expenses by approximately $50 million for 2023 through workforce reductions and other cost containment measures [28] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding demand conditions stabilizing within health systems and hospitals [41] - The company anticipates that gross margin percentage will modestly expand in the second half of 2023 due to cost containment actions and expected volume leverage [69] - Management acknowledged ongoing macroeconomic uncertainties but remains confident in the long-term growth potential of Advanced Services [25][37] Other Important Information - The company announced that Peter Kuipers will step down as CFO on July 1, 2023, after significant contributions to the company [39][40] - The company expects total revenues for 2023 to be between $1.150 billion and $1.190 billion, with product revenue ranging from $740 million to $760 million [49] Q&A Session Questions and Answers Question: Is the announced savings factored into the guidance for the full year? - The savings are not specifically factored into the guidance, but the company continues to see strong demand for Advanced Services [78] Question: What is the outlook for the Specialty Pharmacy business? - The company is optimistic about the growth of the Specialty Pharmacy offering, viewing it as a significant growth driver for 2023 and beyond [109] Question: How is the company managing capital allocation moving forward? - The company is prioritizing maintaining a large cash balance and is cautious about M&A and strategic acquisitions in the current environment [87]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNICELL, INC. (Exact name of regis ...

Omnicell, Inc. (NASDAQ:OMCL) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Chairman, President, Chief Executive Officer, and Founder Scott Seidelmann - Executive Vice President and Chief Commercial Officer Peter Kuipers - Executive Vice President and Chief Financial Officer Conference Call Participants Stan Berenshteyn - Wells Fargo Securities Jessica Tassan - Piper Sandler Allen Lutz - Bank of Am ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNICELL ...

Omnicell, Inc. (NASDAQ:OMCL) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Chairman, President, Chief Executive Officer, and Founder Scott Seidelmann - Executive Vice President and Chief Commercial Officer Peter Kuipers - Executive Vice President and Chief Financial Officer Conference Call Participants Joy Zeng - SVB Securities Stan Berenshteyn - Wells Fargo Jessica Tassan - Piper Sandler Lucas Bar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNICEL ...

Omnicell, Inc. (NASDAQ:OMCL) Q1 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Randall Lipps - Chairman, President, Chief Executive Officer Peter Kuipers - Executive Vice President and Chief Financial Officer Scott Seidelmann - Executive Vice President, Chief Commercial Officer Kathleen Nemeth - Senior Vice President, Investor Relations Conference Call Participants Scott Schoenhaus - Stephens Jessica Tassan - Piper Sandler Anne Samuel - JP Morgan Chase Matt Hewitt - Craig-Hallu ...

Investor Relations April 28, 2022 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2022 guidance, 2025 targets, growth targets, other expectations and other non-historical information. Without limiting the foregoing, statements including the words "expect," "intend," "may," "will," "should," "would," "could," "plan," "potential," "anticipate," "believe," "forec ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (650) 251-6100 (Registrant's telephone number, including area cod ...

Investor Relations February 14, 2022 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2022 guidance, 2025 targets, growth targets, other expectations and other non-historical information. Without limiting the foregoing, statements including the words "expect," "intend," "may," "will," "should," "would," "could," "plan," "potential," "anticipate," "believe," "fo ...